Mutational spectrum
Maximal deletion in 1q21.1: 398.5 kb; 3, 5 in 4q34-qter: 8 Mb; 8 in 8p23.1: 1.2 Mb; 7 in 10p14-15: 0.2 Mb; 7 in 16p11.2: 600 kb; 2 in 17q12: 1.5 Mb 2,3,5 and in 22q11.21: 3 Mb. 2, 3, 5, 7, 9, 10 Maximal duplication in 1q21.1: 200 kb. 3 Partial duplication of the Xpter pseudoautosomal region 1. 6 
Analytical methods
Search for microrearrangements by means of multiplex ligationdependent probe amplification (MLPA) using the SALSA P023 DiGeorge MLPA kit (MRC-Holland, Amsterdam, The Netherlands), comparative genomic hybridization array (CGH array), duplex PCR/ liquid chromatography (DP/LC) and/or FISH.
Analytical validation
Validation of MLPA results or CGH array results by DP/LC or FISH.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) 1 in 4500 female births. 11 1.9 If applicable, prevalence in the ethnic group of investigated person Not applicable.
Diagnostic setting
Comment: WNT4 syndrome is close but different from MRKH. It differs from this latter by an hyperandrogenism and gonadal affection. 12 It thus needs to be considered in regards to differential diagnosis. 13 
TEST CHARACTERISTICS

Analytical sensitivity (proportion of positive tests if the genotype is present)
Nearly 100% using analytical methods described above.
Analytical specificity (proportion of negative tests if the genotype is not present)
Nearly 100% using analytical methods described above. The results of genetic tests will influence genetic counselling in case of surrogate pregnancy demand.
